89bio to participate in the oppenheimer 34th annual healthcare life sciences conference

San francisco, feb. 06, 2024 (globe newswire) -- 89bio, inc. (nasdaq: etnb), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the company's management will present at the oppenheimer 34th annual healthcare life sciences conference on tuesday, february 13, 2024 at 1:20 pm est and participate in one-on-one investor meetings.
ETNB Ratings Summary
ETNB Quant Ranking